Sender Co & Partners Inc. Buys Shares of 12,751 Moderna, Inc. (NASDAQ:MRNA)

Sender Co & Partners Inc. acquired a new stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 12,751 shares of the company's stock, valued at approximately $530,000.

A number of other large investors also recently made changes to their positions in MRNA. Norges Bank bought a new position in shares of Moderna during the fourth quarter valued at about $163,833,000. FMR LLC lifted its position in shares of Moderna by 7.4% during the fourth quarter. FMR LLC now owns 18,664,634 shares of the company's stock valued at $776,075,000 after purchasing an additional 1,282,469 shares in the last quarter. Pictet Asset Management Holding SA lifted its position in shares of Moderna by 170.5% during the fourth quarter. Pictet Asset Management Holding SA now owns 1,766,398 shares of the company's stock valued at $73,447,000 after purchasing an additional 1,113,455 shares in the last quarter. Invesco Ltd. lifted its position in shares of Moderna by 24.3% during the fourth quarter. Invesco Ltd. now owns 5,006,462 shares of the company's stock valued at $208,169,000 after purchasing an additional 979,858 shares in the last quarter. Finally, Renaissance Technologies LLC raised its position in Moderna by 225.7% in the fourth quarter. Renaissance Technologies LLC now owns 1,010,758 shares of the company's stock worth $42,027,000 after acquiring an additional 700,458 shares during the period. 75.33% of the stock is owned by institutional investors.

Moderna Stock Performance

MRNA stock traded up $1.60 during midday trading on Tuesday, reaching $27.99. 37,101,521 shares of the company were exchanged, compared to its average volume of 7,944,045. The stock's 50-day simple moving average is $27.70 and its 200 day simple moving average is $35.11. The company has a market cap of $10.82 billion, a price-to-earnings ratio of -3.02 and a beta of 1.99. Moderna, Inc. has a 1-year low of $23.15 and a 1-year high of $170.47.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, topping the consensus estimate of ($2.92) by $0.40. The company had revenue of $108.00 million for the quarter, compared to analyst estimates of $130.35 million. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The business's revenue was down 35.3% on a year-over-year basis. During the same period in the previous year, the firm earned ($3.07) EPS. On average, research analysts anticipate that Moderna, Inc. will post -9.61 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. The Goldman Sachs Group cut shares of Moderna from a "buy" rating to a "neutral" rating and reduced their price objective for the company from $99.00 to $51.00 in a research note on Wednesday, January 29th. Citigroup assumed coverage on shares of Moderna in a research note on Thursday, March 13th. They set a "neutral" rating and a $40.00 price objective for the company. William Blair reaffirmed a "market perform" rating on shares of Moderna in a research note on Thursday, April 17th. Morgan Stanley cut their price target on shares of Moderna from $39.00 to $32.00 and set an "equal weight" rating for the company in a research note on Wednesday, April 9th. Finally, Barclays lowered their price target on shares of Moderna from $45.00 to $40.00 and set an "equal weight" rating for the company in a research note on Friday, May 2nd. Four equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Moderna presently has a consensus rating of "Hold" and an average price target of $53.95.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.